Resolvyx Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Resolvyx Pharmaceuticals is developing a new class of lipid mediators, dubbed resolvins, which are generated through the oxidation of the omega-3 fatty acids EPA and DHA. Although omega-3 fatty acids have long been heralded for their reputed ability to reduce inflammation, many grams of omega-3 fatty acids have to be consumed to produce any physiological effect. In contrast, Resolvyx says its resolvins are potent at low milligram quantities and so are good candidates for commercialization as drugs. Resolvyx is advancing two programs into the clinic.
You may also be interested in...
Start-Ups Against Inflammation
Inflammation plays a part in a wide range of diseases across a broad spectrum of markets, including the huge and already crowded, like rheumatoid arthritis; the difficult to navigate, like Crohn's disease; and the emerging, like atherosclerosis. Start-ups looking to compete in inflammation can boost their chances of success by focusing on niche indications or on drug targets with broad applicability, and thus attract the attention of in-licensers or acquirers. In this issue, we profile four young companies hoping to prove the worth of their technologies to investors and partners alike.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Against Inflammation," features profiles of Asphleia Pharmaceuticals, Calistoga Pharmaceuticals, ProtAb Ltd., and Resolvyx Pharmaceuticals. Plus these Start-Ups Across Health Care: CG Therapeutics, Healionics, Mpathy Medical Devices and Pronostics.
Start-Ups Against Inflammation
Inflammation plays a part in a wide range of diseases across a broad spectrum of markets, including the huge and already crowded, like rheumatoid arthritis; the difficult to navigate, like Crohn's disease; and the emerging, like atherosclerosis. Start-ups looking to compete in inflammation can boost their chances of success by focusing on niche indications or on drug targets with broad applicability, and thus attract the attention of in-licensers or acquirers. In this issue, we profile four young companies hoping to prove the worth of their technologies to investors and partners alike.